

PROTOCOL CODE: UGUMCSPDD

(Page 1 of 2)

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment

DOCTOR'S ORDERS			Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form					
DATE:	To be given:	Cycle #: _____			
Date of Previous Cycle:					
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff, platelets day of treatment					
<p>For Cycles 1 to 6: May proceed with DOCEtaxel as written if within 96 hours ANC <u>greater than or equal to 1.5 x 10⁹/L</u>, platelets <u>greater than 90 x 10⁹/L</u> and (if ordered), <u>total bilirubin less than or equal to ULN</u>, alkaline phosphatase <u>less than 2.5 x ULN</u> (unless bone metastases), and <u>ALT less than or equal to 1.5 x ULN</u></p> <p>For Cycles 1 to 6: May proceed with darolutamide if within 96 hours ANC <u>greater than or equal to 1.0 x 10⁹/L</u>, and platelets <u>greater than or equal to 50 x 10⁹/L</u></p> <p>Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity: _____</p> <p>Proceed with treatment based on blood work from _____</p>					
<p>PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.</p> <p>dexamethasone 8 mg PO bid for 3 days, starting one day prior to DOCEtaxel; patient must receive a minimum of 3 doses pretreatment</p> <p>Optional: Frozen gloves starting 15 minutes before DOCEtaxel infusion until 15 minutes after end of DOCEtaxel infusion; gloves should be changed after 45 minutes of wearing.</p> <p><input type="checkbox"/> Other:</p>					
Have Hypersensitivity Reaction Tray and Protocol Available					
<p>TREATMENT:</p> <p><input type="checkbox"/> CYCLES 1 to 6 (DOCEtaxel and darolutamide combination treatment)</p> <p>DOCEtaxel 75 mg/m² x BSA = _____ mg</p> <p><input type="checkbox"/> Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg IV in 250 to 500 mL (non-DEHP bag) NS over one hour (use non-DEHP tubing)</p> <p>darolutamide 600 mg PO twice daily.</p> <p>Dose modification:</p> <p><input type="checkbox"/> darolutamide 300 mg PO twice daily.</p> <p>Mitte: _____ days (maximum 90 days). Repeat x _____</p> <p>Remember to commence standard androgen deprivation therapy (i.e., LHRH agonist, LHRH antagonist)</p>					
Continued on Page 2					
DOCTOR'S SIGNATURE:				SIGNATURE:	
				UC:	



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: UGUMCSPDD

(Page 2 of 2)

TREATMENT, continued:

CYCLES 7 onwards (darolutamide treatment)

darolutamide 600 mg PO twice daily.

Dose modification:

darolutamide 300 mg PO twice daily.

Mitte: _____ days (maximum 90 days). Repeat x _____

Remember to continue standard **androgen deprivation therapy** (i.e., LHRH agonist, LHRH antagonist)

RETURN APPOINTMENT ORDERS

Return in **three** weeks for Doctor and Cycle _____

Return in _____ weeks for Doctor and Cycle _____

Last Cycle. Return in _____ week(s).

Cycles 1 to 6 (DOCEtaxel and darolutamide combination treatment): **CBC & Diff, platelets and PSA** prior to each cycle

Prior to Cycle 4 and as clinically indicated for Cycles 1 to 6: **ALT, alkaline phosphatase, total bilirubin, LDH**

Cycles 7 onward (darolutamide treatment): **PSA, testosterone** prior to each physician visit

If clinically indicated for Cycles 7 onward:

ECG **calcium** **albumin** **total bilirubin** **ALT** **INR**

random glucose **HbA1c** **creatinine** **sodium** **potassium**

TSH

Other tests:

Consults:

See general orders sheet for additional requests.

DOCTOR'S SIGNATURE:

SIGNATURE:

UC: